<DOC>
	<DOC>NCT00426660</DOC>
	<brief_summary>To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.</brief_summary>
	<brief_title>Expanded Access Program for Maraviroc At Multiple Centers</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Subjects must be failing to achieve adequate virologic suppression on their current regimen and have HIV1 RNA greater than or equal to 1000 copies/ml, at screening Have only R5 HIV1 at Screening as verified by the Monogram Biosciences Trofile assay Minimum age must be 16 years or minimum adult age as determined by local regulatory authorities or directed by local law. Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trial or having previously prematurely discontinued Maraviroc in trials</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV Infections</keyword>
</DOC>